GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (NAS:ARNA) » Definitions » PS Ratio

Arena Pharmaceuticals (Arena Pharmaceuticals) PS Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arena Pharmaceuticals's share price is $99.99. Arena Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00. Hence, Arena Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Arena Pharmaceuticals's PS Ratio or its related term are showing as below:

ARNA' s PS Ratio Range Over the Past 10 Years
Min: 2.71   Med: 29.29   Max: 99990
Current: 99990

During the past 13 years, Arena Pharmaceuticals's highest PS Ratio was 99990.00. The lowest was 2.71. And the median was 29.29.

ARNA's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 8.92 vs ARNA: 99990.00

Arena Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2021 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00.

Warning Sign:

Arena Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Arena Pharmaceuticals was -83.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -86.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -77.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -39.00% per year.

During the past 13 years, Arena Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 60.20% per year. The lowest was -86.20% per year. And the median was -11.80% per year.

Back to Basics: PS Ratio


Arena Pharmaceuticals PS Ratio Historical Data

The historical data trend for Arena Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals PS Ratio Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.50 101.96 2.91 12,805.00 92,940.00

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,805.00 - - - -

Competitive Comparison of Arena Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Arena Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's PS Ratio falls into.



Arena Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Arena Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=99.99/0.001
=

Arena Pharmaceuticals's Share Price of today is $99.99.
Arena Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Arena Pharmaceuticals  (NAS:ARNA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Arena Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Executives
Amit Munshi director, officer: President and CEO C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Robert Lisicki officer: EVP, Chief Commercial Officer C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Dallas Jayson Donald Alexander director AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Vincent Aurentz officer: Executive VP and CBO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Christopher Cabell officer: EVP, Head of R&D, and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Oliver Fetzer director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Laurie Stelzer officer: EVP & Chief Financial Officer 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Joan Schmidt officer: EVP, General Counsel & Sec C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Kevin Robert Lind officer: Executive VP and CFO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121